Equity Research, Broker Reports, and media content on Basilea Pharmaceutica AG

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Basilea Pharmaceutica AG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 10 Apr 24
Basilea Pharmaceutica - CARB-X grant for preclinical programs

In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership backed by governments and foundations, for its preclinical antibiotics program. CARB-X is focused on supporting early-stage antibacterial research and development, and this grant is expected to support development work up until clinical candid

Companies: Basilea Pharmaceutica AG

Edison
  • 04 Apr 24
Basilea Pharmaceutica - Zevtera crosses key US regulatory hurdle

Basilea has announced the FDA approval of its second lead asset, Zevtera (ceftobiprole), for the treatment of severe bacterial infections (three indications), marking a major commercial win. The US is the most commercially lucrative market for Zevtera, accounting for 85–90% of its total market potential. Zevtera is already approved in several countries (including in Europe) and the FDA nod is based on three Phase III studies (including the ERADICATE and TARGET studies with R&D partly funded by t

Companies: Basilea Pharmaceutica AG

Edison
  • 04 Apr 24
FDA approves Zevtera

Zevtera has been approved by FDA for the treatment of Staphylococcus aureus bacteraemia (SAB) amongst other indications. There is a real unmet need for patients suffering from SAB, with Basilea noting that there are approximately 120,000 cases in the US. We are optimistic about the outlook for ceftobiprole, which is reflected in our $400m peak sales potential. The approval provides Bailea with a product at the beginning of its life cycle thanks to the protection offered by QIDP status. The app

Companies: Basilea Pharmaceutica AG

Calvine Partners
  • 11 Mar 24
Basilea Pharmaceutica - Strong Cresemba traction triggers milestone payment

Continued strong sales of Cresemba, Basilea Pharmaceutica’s lead antifungal asset, in the Asia-Pacific region and China, has triggered the receipt of a US$1.25m milestone payment from Pfizer (license partner). This comes on the heels of Basilea’s first sales-related milestone from distribution partner Knight Therapeutics in January for sales in Latin America. We believe these reflect sustained market traction for Cresemba, leading to in-market sales of US$445m in the 12 months ending September 2

Companies: Basilea Pharmaceutica AG

Edison
  • 04 Mar 24
Interview with David Veitch, CEO of Basilea Pharmaceutica

Premium

interview-with-david-veitch-ceo-of-basilea-pharmaceutica-04-03-2024
  • 28 Feb 24
Anti-infectives ascendancy

FY’23 has been a year of excellent execution, both financially and strategically. The acquisition of fosmanogepix brings Basilea a Phase 3-ready novel antifungal and removes much of the uncertainty created by Cresemba's likely loss of exclusivity in UK and Europe in 2027. Clinical data generated by originator Amplyx (now a Pfizer subsidiary), demonstrates that fosmanogepix possesses several important attributes that point to a commercially successful treatment option in various critical fungal i

Companies: Basilea Pharmaceutica AG

Calvine Partners
  • 20 Feb 24
Basilea Pharmaceutica - From strength to strength

FY23 was another strong year for Basilea, marked by successive guidance beats and meaningful progress in fortifying its product pipeline. Revenues of CHF157.6m were ahead of guidance, driven by c 23% y-o-y growth in Cresemba- and Zevtera-related revenues to CHF150.3m. Top-line growth, combined with operational prudence (despite investments in growing its portfolio), supported Basilea in achieving a second successive year of net profitability (CHF10.5m, c 2x the guided figure). FY24 will be an im

Companies: Basilea Pharmaceutica AG

Edison
  • 26 Jan 24
Basilea Pharmaceutica - Strong close to FY23 with another milestone payment

Basilea has announced receipt of its first sales-related milestone (for an undisclosed amount) from distribution partner Knight Therapeutics. The payment was triggered by combined Cresemba sales in Latin America exceeding a pre-defined sales threshold. Cresemba continues to see strong market traction for the treatment of invasive aspergillosis and mucormycosis, with the drug reporting in-market sales of US$445m in the 12 months ending September 2023 (+22% y-o-y), reflecting a growing market shar

Companies: Basilea Pharmaceutica AG

Edison
  • 17 Jan 24
Basilea Pharmaceutica - Antibiotic addition to further replenish pipeline

Basilea has announced a preclinical antibiotic programme asset purchase agreement, aligning with management’s pre-emptive efforts to refill its pipeline with novel anti-infectives. This follows on the heels of three antifungal and antibacterial acquisitions/in-licensing, including fosmanogepix. As part of the agreement, Basilea will pay Spexis (SIX: SPEX) up to CHF2m, consisting of an upfront payment, an asset-transfer payment and a potential final milestone payment related to the availability o

Companies: Basilea Pharmaceutica AG

Edison
  • 05 Jan 24
Basilea portfolio update

Basilea provides a timely reminder of the ongoing robust performance of the existing anti-infectives portfolio, along with a summary of plans for 2024.

Companies: Basilea Pharmaceutica AG

Calvine Partners
  • 22 Dec 23
Basilea Pharmaceutica - Refilling the pipeline for growth

Basilea recently expanded its antifungal and antibacterial product pipeline with three new assets, including the latest addition, fosmanogepix. As a broad-spectrum antifungal (including multidrug-resistant fungi), fosmanogepix has a novel mechanism of action, a key differentiator in the rise of antifungal drug resistance. Two Phase III trials are expected to commence in mid- and late-2024 (in candidemia/invasive candidiasis and invasive mould infections, respectively) and a successful launch has

Companies: Basilea Pharmaceutica AG

Edison
  • 12 Dec 23
Edison’s most frequently asked questions - Basilea Pharmaceutica

Premium

edison-s-most-frequently-asked-questions-basilea-pharmaceutica-12-12-2023
  • 14 Nov 23
Basilea Pharmaceutica - Incremental acquisition to arsenal; new guidance

Basilea has bolstered its drug pipeline with the in-licensing of fosmanogepix, a broad-spectrum antifungal candidate, from Amplyx Pharmaceuticals (a Pfizer affiliate). Fosmanogepix is a clinical-stage, potentially first-in-class broad-spectrum antifungal treatment and Basilea plans to initiate Phase III trials in mid-2024. Deal consideration includes $37m in upfront payments and milestones of up to $496m ($110m to Pfizer, and $396m from previous agreements), of which the majority relates to regu

Companies: Basilea Pharmaceutica AG

Edison
  • 09 Nov 23
Basilea Pharmaceutica – executive interview

Premium

basilea-pharmaceutica-executive-interview-09-11-2023
  • 01 Nov 23
Basilea Pharmaceutica - Growth pivot with potential antibacterial addition

Basilea has announced an exclusive evaluation licence and option agreement with South Korea-based iNtRON Biotechnology (KOSDAQ: 048530) for tonabacase, a potential first-class antibacterial of endolysin class. The product candidate could potentially fit well into Basilea’s portfolio of anti-fungal and anti-bacterial products, Cresemba and Zevtera. This announcement follows the recent in-licensing of GR-2397 (an antifungal compound, renamed BAL2062) and aligns with management’s strategic focus to

Companies: Basilea Pharmaceutica AG

Edison

Basilea Pharmaceutica AG

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Basilea Pharmaceutica AG. We currently have 26 research reports from 4 professional analysts.

Latest News/RNS

(more news)
Date Source Announcement
07Jan20 09:48 EQS Edison Investment Research Limited: Edison issues outlook on Basilea Pharmaceutica (BSLN)
23Apr19 11:27 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05 EQS Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15 GNW Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15 GNW Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Basilea Pharmaceutica AG

  • Providers covering

    Basilea Pharmaceutica AG